Yes, most of them can be reimbursed by medical insurance, and the price is also very high. You just need to cooperate with the doctor's treatment, and don't think about money. The general formula for medical insurance reimbursement is as follows: reimbursement amount = [total cost of treatment - minimum payment

Line - self-paid part]_Reimbursement ratio (70%-90%) Note: The threshold is the treatment cost that exceeds the minimum limit, which can be reimbursed. The threshold varies from region to region, generally 1,000-2,000 yuan.

The maximum reimbursement amount, that is, the amount of reimbursement cannot exceed the maximum limit, which also varies from region to region, and is generally several hundred thousand.

1. How can medical insurance reimburse? The reimbursement process of medical insurance: 1. The handler submits reimbursement documents and other materials to the social security agency for acceptance; 2. After the acceptance department receives the application materials, the medical insurance center completes the review, settlement, and payment on the same day; 3.

The social security agency will review the materials and approve the application, and the applicant will be reimbursed after receiving the social medical insurance medical expense reimbursement form.

Legal basis: Article 26 of the "Social Insurance Law of the People's Republic of China" The treatment standards of basic medical insurance for employees, new rural cooperative medical care and basic medical insurance for urban residents shall be implemented in accordance with national regulations.

Article 28 of the "Social Insurance Law of the People's Republic of China" meets the basic medical insurance drug catalog, diagnosis and treatment items, medical service facility standards, and emergency and rescue medical expenses, and shall be paid from the basic medical insurance fund in accordance with national regulations.

2. PD-1 PD-1 (programmed death receptor 1), also known as CD279 (cluster of differentiation 279), is an important immunosuppressive molecule.

Modulates the immune system and promotes self-tolerance by down-regulating the immune system's response to human cells, and by inhibiting T cell inflammatory activity.

This prevents autoimmune diseases, but it also prevents the immune system from killing cancer cells.

In December 2018, Sintilimab injection, the first domestically produced PD-1 antibody drug for the treatment of Hodgkin lymphoma, was approved for marketing.

The approval of "Tyvyt" marks the entry of anti-tumor immunotherapy into the "China Innovation Era".

In November 2019, Tyvyt (scientific name: sintilimab injection) was included in the Category B scope of the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2019 Edition)", becoming the only drug included in the national medical insurance catalog.

PD-1 anticancer drug.

In December 2019, the domestically produced PD-1 antibody drug - tislelizumab (generic name: tislelizumab injection) was approved for marketing, and domestic tumor immunotherapy has further developed.

Tislelizumab is not only BeiGene’s first independently developed new anti-cancer drug approved for marketing in China, but also BeiGene’s first tumor immunotherapy drug in the world.